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Abstract
Background: Previous studies have demonstrated that centrally administered natriuretic peptides
and pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) have hyperthermic
properties. Isatin (indole-2, 3-dione) is an endogenous indole that has previously been found to
inhibit hyperthermic effects of natriuretic peptides. In this study the aim was to investigate the
effects of isatin on thermoregulatory actions of PACAP-38, in rats.
Results: One µg intracerebroventricular (icv.) injection of PACAP-38 had hyperthermic effect in
male, Wistar rats, with an onset of the effect at 2 h and a decline by the 6th h after administration.
Intraperitoneal (ip.) injection of different doses of isatin (25-50 mg/kg) significantly decreased the
hyperthermic effect of 1 µg PACAP-38 (icv.), whereas 12.5 mg/kg isatin (ip.) had no inhibiting effect.
Isatin alone did not modify the body temperature of the animals.
Conclusion:  The mechanisms that participate in the mediation of the PACAP-38-induced
hyperthermia may be modified by isatin. The capability of isatin to antagonize the hyperthermia
induced by all members of the natriuretic peptide family and by PACAP-38 makes it unlikely to be
acting directly on receptors for natriuretic peptides or on those for PACAP in these hyperthermic
processes.
Background
Pituitary adenylate cyclase-activating polypeptide (PAC-
AP) is known as a member of a superfamily that includes
vasoactive intestinal polypeptide (VIP), secretin, gluca-
gon, gastric inhibitory polypeptide and growth hormone-
releasing factor [9]. The biologically active neuropeptide
exists in two amidated forms: PACAP-38, a 38-amino-acid
polypeptide; and PACAP-27, a truncated form of PACAP-
38 containing 27 residues [4]. Both PACAP-38 and PAC-
AP-27 are potent in stimulating adenylate cyclase.
At least two receptor classes have been reported for PACAP
in mammalian tissues: type I and type II. Type I receptors
are highly selective in the recognition of PACAP, and have
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lower affinity for VIP. Type II receptors display similar
high affinity for PACAP-27, PACAP-38 and VIP [2]. Type
II (VIP-PACAP) receptors interact almost exclusively with
adenylate cyclase. At least two effector systems exist for
type I PACAP-preferring receptors, which can stimulate
both adenylate cyclase and phospholipase C. Subsequent
to phospholipase C activation via the inositol phosphate
cascade, a secondary Ca2+ entry elevating cytosolic [Ca2+]
follows Ca2+ mobilization [9].
Recent investigations carried out in our laboratory dem-
onstrated that PACAP-38 [5] induced dose-dependent el-
evations in the body temperature of rats when injected
centrally. Different members of the natriuretic peptide
family had a similar effect [7]. The natriuretic peptides-in-
duced hyperthermia was abolished by the endogenous in-
dole isatin (indole-2, 3-dione) [6]. Isatin has been found
to act as an antagonist at natriuretic peptide receptors of
the brain and heart, and it may well be that isatin is an en-
dogenous inhibitor of these peptides at a central level [3].
Although the antagonism by isatin of some of the behav-
ioral effects of ANP has been described [1], much remains
to be understood concerning the interaction of isatin and
neuropeptide systems.
The present study was carried out to investigate the effects
of isatin on PACAP-38- induced hyperthermia.
Results
Effects of isatin on the PACAP-38-induced hyperthermia
I.c.v. administration of PACAP-38 (1 µg) elevated the co-
lon temperature 2, 3, 4, 5 and 6 h after administration.
These observations were in accordance with our previous-
ly published data [5]. An I.p. injection of different doses
of isatin (18.75, 25 and 50 mg/kg) 3.5 h after peptide
treatment significantly diminished the hyperthermia in
PACAP-38-treated animals at 4 and 5 h in a dose-depend-
ent manner [F (9, 97)2,3,4,5,6 h = 3.75, 24.26, 22.71, 24.91,
20.21; p < 0.05]. Isatin had no antihyperthermic effect at
6 h (Fig. 1). Control injections of isatin (12.5, 18.75, 25
and 50 mg/kg; i.p.) 3.5 h after i.c.v. saline administration
did not modify the colon temperature (data not shown).
Discussion
We have previously demonstrated that central administra-
tion of PACAP-38 produces a long lasting hyperthermia in
rats, raising the possibility that this neuropeptide plays a
part in thermoregulatory processes at a central level. No
effect of the peptide on body temperature is seen 24 h af-
ter injection [5]. Other results provided evidence that the
endogenous indole isatin inhibited the hyperthermia in-
duced by natriuretic peptides [6].
The effects of isatin on PACAP-38-induced hyperthermia
were investigated in this study. Injections of PACAP-38
into the lateral ventricle of the brain elevated the body
temperature of the experimental animals with an onset of
the hyperthermia at 2 h and a decline at 6 h. Single injec-
tions of isatin doses after the onset of the peptide-induced
hyperthermia diminished the hyperthermic effect of PAC-
AP-38 whereas isatin itself did not modify the body tem-
perature. A positive correlation was observed between the
antihyperthermic effect and the dose of isatin adminis-
tered. No effect of the indole on hyperthermia was shown
2.5 h after injection.
An unpublished pilot study in our laboratory indicated
that isatin did not have noticeable effect on the hyperther-
mia induced by PACAP-38 when injected before the onset
of the body temperature elevation. This accounted for the
isatin treatment 3.5 h after PACAP injection but does not
support a possible interaction between PACAP receptors
and the indole in the antihyperthermic effect of isatin.
The present results demonstrate that isatin is able to di-
minish the hyperthermic effect of neuropeptides other
than natriuretic peptides, namely that of PACAP-38. The
capability of isatin to antagonize the hyperthermia in-
duced by all members of the natriuretic peptide family
and also by PACAP-38 raises the possibility of common
Figure 1
Effects of isatin on PACAP-38-induced hyperthermia. Groups
of rats received an i.p. injection of saline (PACAP 1 µg group)
or different doses (12.5, 18.75, 25 or 50 mg/kg) of isatin (Isa.
+ PACAP groups) 3.5 h after an i.c.v. injection of 1 µg
PACAP-38. The control group received an i.p. saline injec-
tion 3.5 h after i.c.v. saline treatment (groups of animals
receiving different dilutions (12.5, 18.75, 25 or 50 mg/kg; i.p.)
of isatin 3.5 h after an i.c.v. saline injection are not shown).
Number of animals per group is presented in parentheses
after the corresponding group. The vertical lines on the top
of the marks denote the S.E.M. The vertical arrow denotes
the time of isatin injection (3.5 h). * p < 0.05 PACAP vs.
other groups; ×  p < 0.05 control vs. other groups; ** p < 0.05
Isa. 18.75 + PACAP compared with the control, the Isa. 25 +
PACAP, the Isa. 50 + PACAP and with the PACAP 1 µg
groups.BMC Neuroscience 2002, 3 http://www.biomedcentral.com/1471-2202/3/2
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pathways in the mediation of these neuropeptide-induced
hyperthermic actions. However the hyperthermias in-
duced by natriuretic peptides display earlier onset and
shorter duration than that induced by PACAP-38. This
makes it unlikely that isatin acts directly on receptors of
natriuretic peptides or on those of PACAP in these hyper-
thermic processes. Moreover it does not support a possi-
ble action of the indole on an uncharacterized target that
links the actions of natriuretic peptides and PACAP-38 to
each other. To our knowledge no data are yet available on
central actions of PACAP and natriuretic peptides being
interrelated.
The exact mediatory pathway(s) of the PACAP-38-in-
duced hyperthermia has not been clarified. However the
involvement of prostaglandin products and possibly in-
terleukins in the mediation are possible [5]. On the basis
of our present data the connections of isatin to the inter-
leukin-prostaglandin pathway in hyperthermic events and
particularly in the hyperthermic effect of PACAP-38 re-
quire further examination.
Our data indicate that the hyperthermic effect of centrally
administered PACAP-38 is inhibited by isatin in rats and
establishes an in vivo interaction between isatin and PAC-
AP.
Materials and Methods
Animals
The animals were kept and treated under a protocol ac-
cepted by the Committee on Animal Experiments, Univer-
sity of Szeged, Hungary.
Adult male Wistar rats weighing 200-240 g were used.
Each animal was used only once for the experiments. The
animals were housed in groups of 5-6 in cages in a room
maintained at constant temperature (23 ± 1 °C) and on a
standard illumination (lights on from 6 to 18). They had
free access to tap water and standard laboratory food. Rats
were allowed a minimum of 5 days of recovery from sur-
gery before the beginning of experiments.
Surgery
In order to allow intracerebroventricular (i.c.v.) peptide
administration, the rats were implanted with a unilateral
cannula introduced into the right lateral brain ventricle
before the experiment. Under pentobarbital (Nembutal,
Ceva, France; 35 mg/kg) intraperitoneal (i.p.) anesthesia,
the stainless steel cannula was inserted stereotaxically into
the ventricle with coordinates 0.2 mm posterior; 1.7 mm
lateral to the bregma; 3.7 mm deep from the dural surface,
according to the atlas of Pellegrino et al. (1979). The can-
nula was secured with dental acrylic cement. Rats were al-
lowed a minimum of 5 days to recover from surgery
before peptide treatment. Upon the conclusion of the ex-
periments, 10 µl methylene blue was injected into the
ventricle of the decapitated animals and the position of
the cannula was inspected visually. Animals with improp-
er cannula placement were excluded from the final statis-
tical analysis.
Treatments
Rat PACAP-38 was purchased from Bachem (Switzerland)
or was synthesized by G. Tóth. For i.c.v. treatment, differ-
ent doses of PACAP-38 were dissolved in sterile pyrogen-
free 0.9% saline and injected in a volume of 2 µl. Isatin
was administered i.p. in doses of 12.5, 18.75, 25 and 50
mg/kg, diluted in saline in a volume of 2.5 ml/kg. The
control groups were treated with saline for all experi-
ments.
Procedures
On the day of the experiment, the animals were trans-
ferred to the laboratory 2 h before the beginning of the
test in order for them to habituate to the experimental en-
vironment. The room temperature was maintained at 23.0
± 0.5°C throughout the experiment. Each animal was then
removed from the cage and gently restrained with a cloth
on the table. The colon temperature was monitored by in-
serting the vaseline-lubricated thermistor probe of a digit-
al electric thermometer (Model: Cole-Parmer 8402-10) 5
cm into the rectum of the animal. The probe was inserted
the same distance into the rectum each time it was used.
The experiments started at 8 a.m. with an initial colon
temperature measurement, the colon temperature also be-
ing measured before and 1, 2, 3, 4, 5 and 6 h after peptide
treatment.
The effects of i.p. administered isatin on the PACAP-38-in-
duced hyperthermia were studied. Different doses (12.5,
18.75, 25, 50 mg/kg) of isatin were given i.p. once 3.5 h
after i.c.v. peptide treatment (PACAP-38 being injected in
a dose of 1 µg) and the colon temperature was measured
1, 2, 3, 4, 5 and 6 h later.
Statistical analysis
Statistical analysis of the data was made by analysis of var-
iance (ANOVA). For significant ANOVA values, groups
were compared by Tukey's test for multiple comparisons
with unequal cell size. A probability level of 0.05 was ac-
cepted as indicating significant differences.
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